Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Susan Kubik"'
Autor:
Eva-Maria Muchitsch, Barbara Dietrich, Susan Kubik, Hans Peter Schwarz, Christina Piskernik, Tanja Ruthsatz, Friedrich Scheiflinger
Publikováno v:
Blood. 120:3381-3381
Abstract 3381 Baxter is currently developing a recombinant ADAMTS13 (rADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) product for treatment, and routine prophylaxis of acute episodes of thrombotic thromboc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3c5516f4a2e26f19cada26c60f2f9821
https://doi.org/10.1182/blood.v120.21.3381.3381
https://doi.org/10.1182/blood.v120.21.3381.3381
Autor:
Hartmut J. Ehrlich, Susan Kubik, Barbara Dietrich, Friedrich Scheiflinger, Eva-Maria Muchitsch, Hans Peter Schwarz
Publikováno v:
Blood. 118:4357-4357
Abstract 4357 Baxter has developed a PEGylated recombinant human factor VIII conjugate by modifying the FVIII molecule with polyethylene glycol (PEGylation). The product is derived from a CHO cell line using a plasma-protein-free method and a virus i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5a163450cf2cc75c0b07561a88064bc7
https://doi.org/10.1182/blood.v118.21.4357.4357
https://doi.org/10.1182/blood.v118.21.4357.4357
Autor:
Herbert Gritsch, Susan Kubik, Hans Peter Schwarz, Eva-Maria Muchitsch, Martin J. Wolfsegger, Friedrich Scheiflinger, Hartmut J. Ehrlich, Alfred L. Weber, John-Philip Lawo, Gerald Hoebarth
Publikováno v:
Blood. 116:4655-4655
Abstract 4655 The purpose of these PK studies was to assess the pharmacokinetic profile of Baxter's rFVIIa in comparison with a commercially available rFVIIa after a single intravenous bolus injection at a target dose of 0.6 mg/kg BW in mice and rats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::309055f834afe79e8304727ec5a6374c
https://doi.org/10.1182/blood.v116.21.4655.4655
https://doi.org/10.1182/blood.v116.21.4655.4655
Autor:
Barbara Dietrich, Frank M. Horling, Hans Peter Schwarz, Hartmut J. Ehrlich, Eva-Maria Muchitsch, Friedrich Scheiflinger, Wilfried Auer, Birgit M. Reipert, Susan Kubik
Publikováno v:
Blood. 116:1417-1417
Abstract 1417 Baxter has developed a recombinant FVIIa (rFVIIa) product for the treatment of patients with hemophilia A and hemophilia B with inhibitors. Baxter's new rFVIIa is produced by a genetically engineered Chinese hamster ovary (CHO) cell lin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b200211c0048204fd31923bea00408ec
https://doi.org/10.1182/blood.v116.21.1417.1417
https://doi.org/10.1182/blood.v116.21.1417.1417
Autor:
Barbara Dietrich, Susan Kubik, Wilfried Auer, Kuno Wuersch, Birgit Reipert, Frank Horling, Martin Wolfsegger, Hartmut J. Ehrlich, Friedrich Scheiflinger, Hans Peter Schwarz, Eva-Maria Muchitsch
Publikováno v:
Blood. 116:4654-4654
Abstract 4654 Baxter has developed a rFIX product which is produced by a genetically engineered Chinese hamster ovary (CHO) cell line in a cell culture medium free from any animal or human proteins. The objective of this preclinical study-program was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::006d1a8b837a16d57ba475fd8c3784e5
https://doi.org/10.1182/blood.v116.21.4654.4654
https://doi.org/10.1182/blood.v116.21.4654.4654
Autor:
Wilfried Auer, Hans Peter Schwarz, Jackie Kunzler, Susan Kubik, Jerome Gass, Peter Turecek, Martin J. Wolfsegger, Alfred L. Weber, Eva M. Muchitsch
Publikováno v:
Chest. 130:183S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6156326bc9c3879d391fb8910db64792
https://doi.org/10.1378/chest.130.4_meetingabstracts.183s-c
https://doi.org/10.1378/chest.130.4_meetingabstracts.183s-c